News
20 July 2023
Accelerated In-Vitro Release?
Establishing an in-vitro / in-vivo correlation is challenging in the development and testing of pharmaceutical formulations. A discrepancy leads to difficulties in accurately predicting how the formulation will behave and perform in the human body.
Such discrepancies can compromise the reliability of in-vitro testing as a surrogate for real-world drug release, leading to delays in formulation optimisation and hindering the ability to accurately assess bioequivalence. Overcoming these barriers is critical to ensuring safe and effective drug delivery systems.
A current research project that addresses this difficult correlation comes from Texas Southern University. In-vitro drug release tests are crucial for the development of polylactide-co-glycolide (PLGA)-based formulations, as they often exhibit slower release than under in-vivo conditions. The aim of this study was to accelerate the release of AC1LPSZG, a poorly soluble chemotherapeutic agent, by using surfactants in PLGA nanoparticles (NPs).
Published 29 November 2022
Pharmaceuticals, Volume 15, Issue 12 (December 2022).
Abstract:
"In-vitro drug release testing is an important quality control tool for formulation development. However, the literature has evidence that poly-lactide-co-glycolide (PLGA)-based formulations show a slower in-vitro drug release than a real in-vivo drug release. Much longer in-vitro drug release profiles may not be reflective of real in-vivo performances and may significantly affect the timeline for a formulation development. The objective of this study was to develop a surfactant mediated accelerated in-vitro drug release method for the PLGA nanoparticles (NPs) of a novel chemotherapeutic agent AC1LPSZG, a model drug with a poor solubility. The Sotax USP apparatus 4 was used to test in-vitro drug release in a phosphate buffer with a pH value of 6.8. [...]"
If you are looking for more exciting articles in this area, we recommend the freely available special issue "Solubilization and Controlled Release Strategy of Poorly Water-Soluble Drugs" from MDPI.
Are your next developments based on accelerated in-vitro release profiles? Contact us to learn more about the possibilities of flow-through cell dissolution.